MedPath

GABAPENTIN

These highlights do not include all the information needed to use GABAPENTIN TABLETS safely and effectively. See full prescribing information for GABAPENTIN TABLETS. GABAPENTIN tablets, for oral useInitial U.S. Approval: 1993

Approved
Approval ID

7fcce531-bf7c-43b6-bea9-8f0602842c53

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Apr 1, 2025

Manufacturers
FDA

Proficient Rx LP

DUNS: 079196022

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Gabapentin

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code82804-193
Application NumberANDA214957
Product Classification
M
Marketing Category
C73584
G
Generic Name
Gabapentin
Product Specifications
Route of AdministrationORAL
Effective DateApril 1, 2025
FDA Product Classification

INGREDIENTS (8)

GABAPENTINActive
Quantity: 600 mg in 1 1
Code: 6CW7F3G59X
Classification: ACTIB
MANNITOLInactive
Code: 3OWL53L36A
Classification: IACT
HYDROXYPROPYL CELLULOSE, UNSPECIFIEDInactive
Code: 9XZ8H6N6OH
Classification: IACT
CROSPOVIDONE, UNSPECIFIEDInactive
Code: 2S7830E561
Classification: IACT
TALCInactive
Code: 7SEV7J4R1U
Classification: IACT
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT
GLYCERYL DIBEHENATEInactive
Code: R8WTH25YS2
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT

Drug Labeling Information

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

LOINC: 51945-4Updated: 2/1/2025

INDICATIONS & USAGE SECTION

LOINC: 34067-9Updated: 2/1/2025

CONTRAINDICATIONS SECTION

LOINC: 34070-3Updated: 2/1/2025

WARNINGS AND PRECAUTIONS SECTION

LOINC: 43685-7Updated: 2/1/2025

ADVERSE REACTIONS SECTION

LOINC: 34084-4Updated: 2/1/2025

DRUG INTERACTIONS SECTION

LOINC: 34073-7Updated: 2/1/2025

DOSAGE & ADMINISTRATION SECTION

LOINC: 34068-7Updated: 2/1/2025

DOSAGE FORMS & STRENGTHS SECTION

LOINC: 43678-2Updated: 2/1/2025

USE IN SPECIFIC POPULATIONS SECTION

LOINC: 43684-0Updated: 2/1/2025

DRUG ABUSE AND DEPENDENCE SECTION

LOINC: 42227-9Updated: 2/1/2025

OVERDOSAGE SECTION

LOINC: 34088-5Updated: 2/1/2025

DESCRIPTION SECTION

LOINC: 34089-3Updated: 2/1/2025

CLINICAL PHARMACOLOGY SECTION

LOINC: 34090-1Updated: 2/1/2025

NONCLINICAL TOXICOLOGY SECTION

LOINC: 43680-8Updated: 2/1/2025

CLINICAL STUDIES SECTION

LOINC: 34092-7Updated: 2/1/2025

HOW SUPPLIED SECTION

LOINC: 34069-5Updated: 2/1/2025

INFORMATION FOR PATIENTS SECTION

LOINC: 34076-0Updated: 2/1/2025

SPL MEDGUIDE SECTION

LOINC: 42231-1Updated: 2/1/2025

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

GABAPENTIN - FDA Drug Approval Details